

別紙4
書籍

研究成果の刊行に関する一覧表

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社 名	出版地	出版年	ページ
芥田憲夫 熊田博光	B型・C型肝炎における抗ウイルス療法・抗炎症療法	高久史磨	治療薬ハンドブック2014	じほう	東京	2014	554-560
熊田博光	C型肝炎治療～DAA _s で広がる治療対象～	熊田博光、 茶山一彰、 豊田成司	C型肝炎治療～DAA _s で広がる治療対象～	(株)医薬ジャーナル社	東京	2014	1
鈴木 文孝	NS5A阻害剤	榎本 信幸	HEPATOLOGY PRACTICE Vol.3	文光堂	東京	2014	189-192
鈴木 文孝	C型慢性肝炎治療のガイドライン(厚労省研究班編)の概説	熊田 博光	C型肝炎治療～DAA _s で広がる治療対象～	(株)医薬ジャーナル社	東京	2014	55-62
鈴木 文孝	DAA _s によるIFNフリー療法(IFN free regimen)	熊田 博光	C型肝炎治療～DAA _s で広がる治療対象～	(株)医薬ジャーナル社	東京	2014	108-119
髭修平、 豊田成司	ITPA	榎本信幸、 竹原徹郎、 持田智	Hepatology Practice 「C型肝炎の診療を極める」	文光堂	東京	2014	63-66
平松 直樹、 小瀬 嗣子、 竹原 徹郎	C型肝炎治療の最新展開	竹原徹郎、 金井隆典、 下瀬川徹、 島田光生	Annual Review with 消化器 2015	中外医学社	東京	2015	63-73
大橋 靖雄	生物統計学の世界	大橋 靖雄	生物統計学の往古来今	スコット株)	東京	2014	
坂本穰、 榎本信幸	C型肝炎の治療目標	榎本信幸、 竹原徹郎、 持田智	HEPATOLOGY PRACTICE C型肝炎の診療を極める	文光堂	東京	2014	138-144
坂本穰、 榎本信幸	C型慢性肝炎、肝硬変、	門脇孝ほか 監修、五十嵐隆ほか 責任編集	診療ガイドライン UP-TO-DATE	メディカルレビュー社	大阪	2014	290-296
坂本穰、	DAA 併用療法(IFN based regimen)	熊田博光、 茶山一彰、 豊田成司	C型肝炎治療～DAA _s で広がる治療対象～	医薬ジャーナル社	大阪	2014	89-107

榎本信幸							
川部直人、 吉岡健太郎	エラストグラフィ	榎本信幸、竹原徹郎、持田智	HEPATOLOGY PRACTICE vol 3 C型肝炎の診療を極める 基本から最前線まで	文光堂	東京	2014	73-79
清家正隆	非アルコール性脂肪性肝疾患	福井次矢他	2015今日の治療指針	医学書院	東京	2015	538-539
清家正隆	自己免疫性肝疾患と原発性肝癌	竹原徹郎 持田智 大平弘正 坂井田功	HEPATOLOGY PRACTICE vol4 難治性肝疾患の診療を極める	文光堂	東京	2014	45-49
清家正隆	脾摘・PSE併用IFN療法	竹原徹郎 持田智 榎本信幸	HEPATOLOGY PRACTICE	文光堂	東京	2014	223-228
清家正隆	予後・合併症	日本消化器病学会	NAFLD/NASH診療ガイドライン2014	南江堂	東京	2014	126-136

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Kumada H</u> , Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Timothy E, Fiona M, Andrew D, Ishikawa H, Eric H	Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b infection.	Hepatology	59(6)	2083-2091	2014
<u>Kumada H</u> , Marco daCosta DiBonaventura, Yong Yuan,	The Patient-Related Burden of Pegylated-Interferon- α Therapy and Adverse Events among Patients with Viral Hepatitis C in	V H R I	3	50-58	2014

Anupama Kalsekar, Lewis Kopenhafer, Ann Tang, Timothy W.Victor, Gilbert L'Italien, Chayama K, Toyota J	Japan.				
<u>Kumada H</u> , Sato K, Takehara T, Nakamura M, Ishigami M, Chayama K, Toyota J, Suzuki F, Nakayashu Y, Ochi M, Yamada I, Okanoue T	Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan.	Hpatol Res		Epub ahead of print.	2014
<u>Kumada H</u> , Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S	Simeprevir (TMC435) once daily with peginterferon- α -2b and ribavirin in patients with genotype 1 hepatitis C virus infection; The CONCERTO-4 study.	Hepatol Res		Epub ahead of print.	2014
Suzuki F, Hosaka T, Suzuki Y, Akuta N, Sezaki H, Hara T, Kawamura Y, Kobayashi M, Saitoh S Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, <u>Kumada H</u>	Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine.	J Gastroenterol	49	1094-1104	2014
Hara T, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, <u>Kumada H</u>	Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naive chronic hepatitis B patients.	J Viral Hepat	21	802-808	2014
Suzuki F, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Suzuki Y, <u>Kumada H</u>	Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.	Drug Des Devel	8	869-873	2014
Ikeda K, Kawamura Y, Kobayashi M, Fukushima T, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, <u>Kumada H</u>	Prevention of Disease Progression with Anti-Inflammatory Therapy in Patients with HCV-Related Cirrhosis: A Markov Model.	Oncology	86	295-302	2014

Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, <u>Kumada H</u>	Evolution of Simeprevir-Resistant Variants Over Time by Ultra-Deep Sequencing in HCV Genotype 1b.	J Med Virol	86	1314-1322	2014
Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H</u>	Utility of Detection of Telaprevir-Resistant Variants for Prediction of Efficacy of Treatment of Hepatitis C Virus Genotype 1 Infection.	JCM	52	193-200	2014
Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, <u>Kumada H</u>	Correlation Between Hepatitis B Virus Surface Antigen Level and Alpha-Fetoprotein in Patients Free of Hepatocellular Carcinoma or Severe Hepatitis.	J Med Virol	86	131-138	2014
Arase Y, Kobayashi M, Kawamura Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Sezaki H, Saitoh S, Hosaka T, Ikeda K, <u>Kumada H</u> , Kobayashi T	Impact of Virus Clearance for the Development of Hemorrhagic Stroke in Chronic Hepatitis C.	J Med Virol	86	169-175	2014
Tanaka M, Suzuki F, Seko Y, Hara T, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, <u>Kumada H</u>	Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.	J Gastroenterol	49	470-480	2014
Kobayashi M, Hosaka T, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, <u>Kumada H</u>	Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up.	J Gastroenterol	49	538-546	2014
Kawakami Y, Suzuki F, Karino Y, Toyota J, <u>Kumada H</u> , Chayama K	Telaprevir is effective given every 12 h at 750mg with pegylated interferon- α 2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.	Antiviral Therapy	19	277-285	2014

Phil McEwan, Thomas Ward, Samantha Webster, Yong Yuan, Anupama Kalselar, Kristine Broglio, Kamae I, Melanie Quintana, Scott M.Berry, Kobayashi M, Inoue S, Ann Tang, <u>Kumada H</u>	Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically infected with Hepatitis C Genotype 1b.	V H R I	3C	136-145	2014
Shakado S, Sakisaka S, Okanoue T, Chayama K, Izumi N, Toyoda J, Tanaka E, Ido A, Takehara T, Yoshioka K, Hiasa Y, Nomura H, Seike M, Ueno Y, <u>Kumada H</u>	Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan.	Hepato Res	44	983-992	2014
Kishi A, Hayashi N, Obara K, Aoki K, Yamada I, Ikeda K, <u>Kumada H</u>	Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus.	J AM ACAD DERMATOL	70(3)	584-586	2014
Izumi N, Hayashi N, <u>Kumada H</u> , Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S	Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies.	J Gastroenterol	49	941-953	2014
Hayashi N, Izumi N, <u>Kumada H</u> , Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S	Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase trial.	J Hepatol	61	219-227	2014
Okita K, Izumi N, Ikeda K, Osaki Y, Numata k, Ikeda M, Kokudo N, Imanaka K, Nishiguchi S, Kondo S, Nishigaki Y, Shiomi S, Ueshima K, Isoda N, Karino Y, Kudo M, Tanaka K, Kaneko S, Moriwaki H, Makuuchi M, Okusaka T, Hayashi N, Ohashi Y, <u>Kumada H</u>	The Peretinoin Study Group. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial.	J Gastroenterol		Epub ahead of print	2014

King LY, Canasto-Chibuque C, Johnson KB, Yip S, Chen X, Kojima K, Deshmukh M, Venkatesh A, Tan PS, Sun X, Villanueva A, Sangiovanni A, Nair V, Mahajan M, Kobayashi M, <u>Kumada H</u> , Iavarone M, Colombo M, Fiel MI, Friedman SL, Llovet JM, Chung RT, Hoshida Y	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration.	Gut		Epub ahead of print	2014
Hosaka T, Suzuki F, Kobayashi M, Fukushima T, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, <u>Kumada H</u>	HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleo(s)ide analogue therapy.	Liver Int		Epub ahead of print	2014
Tateishi R, Okanoué T, Fujiwara N, Okita K, Kiyosawa K, Omata M, <u>Kumada H</u> , Hayashi N, Koike K	Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study.	J Gastroenterol		Epub ahead of print	2014
Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, Ikeda K, Osaki Y, Numata K, Nakachi K, Kokudo N, Imanaka K, Nishiguchi S, Okusaka T, Nishigaki Y, Shiomi S, Kudo M, Ido K, Karino Y, Hayashi N, Ohashi Y, Makuuchi M, <u>Kumada H</u>	Peretinoin Study Group. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study.	J Gastroenterol		Epub ahead of print	2014
Arase Y, Heianza Y, Hara S, Ohmoto-Sekine Y, Amakawa K, Tsuji H, Ogawa K, Saito K, Kodama S, Ikeda K, <u>Kumada H</u> , Kobayashi T, Sone H	Potential impact of joint association of alanine aminotransferase and gamma-glutamyltransferase on insulin resistance in Japan: The Toranomon Hospital Health Management Center Study 19(TOPIC 19).	Hepatol Res		Epub ahead of print	2014

Kawamura Y, Ikeda K, Fukushima T, Hara T, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki Y, <u>Kumada H</u>	Potential of a no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: An experimental animal study.	Hepatol Res	44	1234-1240	2014
Sezaki H, Suzuki F, Hosaka T, Akuta N, Fukushima T, Hara T, Kawamura Y, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, <u>Kumada H</u>	Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients.	Hepatol Res	44	163-171	2014
Tomizawa K, Suyama K, Matoba S, Hosaka Y, Toda S, Moriyama J, Shimomura A, Miura Y, <u>Kumada H</u> , Kuroyanagi H, Takano T	The safety of chemotherapy for colorectal cancer patients with hepatitis C virus infection.	Med Oncol	31	212-218	2014
Ikeda K, Izumi N, Tanaka E, Yotsuyanagi H, Takahashi Y, Fukushima J, Kondo F, Fukusato T, Koike K, Hayashi N, Tsubouchi H, <u>Kumada H</u> .	Discrimination of fibrotic staging of chronic hepatitis C using multiple fibrotic markers.	Hepatol Res	44	1047-1055	2014
Suzuki F, Toyota J, Ikeda K, Chayama K, Mochida S, Hayashi N, Ishikawa H, Miyagoshi H, Wenhua Hu, Fiona McPhee, Eric A Hughes, <u>Kumada H</u>	A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.	Antiviral Therapy	19	491-499	2014
Yasui K, Kawaguchi T, Shima T, Mitsuyoshi H, Seki K, Sendo R, Mizuno M, Itoh Y, Matsuda F, <u>Okanoue T.</u>	Effect of <i>PNPLA3</i> rs738409 variant (I148M) on hepatic steatosis, necroinflammation, and fibrosis in Japanese patients with chronic hepatitis C.	J Gastroenterol		Epub ahead of print	2014
Kumada H, Sato K, Takehara T, Nakamura M, Ishigami M, Chayama K, Toyota J, Suzuki F, Nakayasu Y, Ochi M, Yamada I, <u>Okanoue T.</u>	Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan	Hepatol Res		Epub ahead of print	2014

Kumada H, Hayashi N, Izumi N, <u>Okanoue T</u> , Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S.	Simeprevir (TMC435) once daily with peginterferon- α -2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study	Hepatol Res		Epub ahead of print	2014
Hayashi N, Izumi N, Kumada H, <u>Okanoue T</u> , Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S	Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: the CONCERT-1. A phase trial	J Hepatol	61	219-227	2014
Izumi N, Hayashi N, Kumada H, <u>Okanoue T</u> , Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S	Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERT-2 and CONCERT-3 studies.	J Gastroenterol	49	941-953	2014
Shakado S, Sakaida S, <u>Okanoue T</u> , Chayama K, Izumi N, Toyoda J, Tanaka E, Ido A, Takehara T, Yoshioka K, Hiasa Y, Nomura H, Seiki M, Ueno Y, Kumada H.	Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis virus-related liver cirrhosis: A multicenter retrospective study in Japan.	Hepatol Res	44	983-992	2014
Karino T, Ozeki I, Hige S, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Sato T, Ohmura T, <u>Toyota J</u> .	Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir /pegylated interferon /ribavirin therapy for chronic hepatitis C.	J Viral Hepatitis	21	341-347	2014
Sato T, Yamazaki K, Kimura M, <u>Toyota J</u> , Karino Y.	Endoscopic color doppler ultrasonographic evaluation of gastric varices secondary to left-sided portal hypertension.	Diagnostics	4	94-103	2014
Iijima K, Sako M, Nozu K, Mori R, Tsuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, <u>Ohashi Y</u> .	Rituximab for childhood-onset, complicated, frequently, relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomized, placebo-controlled trial	Lancet		Epub ahead of print	2015
Sato I, Makino H, Shimozuma K, <u>Ohashi Y</u> .	Survey of medical care by oncologists for depression in breast cancer patients	Palliative Care Research	9(3)	132-139	2014

Kashiwabara K, Matsuyama Y, <u>Ohashi Y.</u>	A bayesian stopping rule for sequential monitoring of serious adverse events	Therapeutic Innovation & Regulatory Science	48	444-452	2014
Oze T, Hiramatsu N, Yakushijin T, Yamada R, Harada N, Morishita N, Yamada A, Oshita M, Kaneko A, Suzuki K, Inui Y, Tamura S, Yoshihara H, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hayashi N, <u>Takehara T.</u>	The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.	J Gastroenterol.		Epub ahead of print	2014
Oze T, Hiramatsu N, Yakushijin T, Yamada R, Harada N, Morishita N, Oshita M, Mita E, Ito T, Inui Y, Inada M, Tamura S, Yoshihara H, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hayashi N, <u>Takehara T.</u>	The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.	J Viral Hepat.	22(3)	254-262	2015
Hiramatsu N, Oze T, <u>Takehara T.</u>	Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy.	Hepatol Res.	45(2)	152-161.	2015
Fukuda K, Imai Y, Hiramatsu N, Irishio K, Igura T, Sawai Y, Kogita S, Makino Y, Mizumoto R, Matsumoto Y, Nakahara M, Zushi S, Kajiwara N, Oze T, Kawata S, Hayashi N, <u>Takehara T.</u>	Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C.	Hepatol Res.	44(12)	1165-71.	2014
<u>Takehara T.</u>	Simeprevir for the treatment of chronic hepatitis C genotype 1 infection.	Expert Rev Anti Infect Ther..	12(8)	909-917	2014
Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, <u>Takehara T.</u> ; Osaka Liver Forum.	Post-treatment levels of α -fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.	Clin Gastroenterol Hepatol.	12(7)	1186-95.	2014

Morishita N, Hiramatsu N, Oze T, Harada N, Yamada R, Miyazaki M, Yakushijin T, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, <u>Takehara T.</u>	Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis.	J Gastroenterol.	49(7)	1175-82.	2014
Harada N, Hiramatsu N, Oze T, Morishita N, Yamada R, Hikita H, Miyazaki M, Yakushijin T, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Inoue A, Hayashi N, <u>Takehara T.</u>	Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.	J Viral Hepat.	21(5)	357-365.	2014
Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Iio S, Oshita M, Hagiwara H, Mita E, Inui Y, Hijioka T, Inada M, Tamura S, Yoshihara H, Inoue A, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Hayashi N, <u>Takehara T.</u>	Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.	J Gastroenterol.	49(4)	737-47.	2014
Watanabe Y, Yamamoto H, Oikawa R, Toyota M, Yamamoto M, Kondo N, Tanaka S, Arii S, <u>Yotsuyanagi H</u> , Koike K, Itoh F.	DNA methylation at hepatitis B viral integrants is associated with methylation at flanking human genomic sequences.	Genome Res (in press)		Epub ahead of print	2015
Yamada N, Shigefuku R, Sugiyama R, Kobayashi M, Ikeda H, Takahashi H, Okuse C, Suzuki M, Itoh F, <u>Yotsuyanagi H</u> , Yasuda K, Moriya K, Koike K, Wakita T, Kato T.	Acute hepatitis B of genotype H resulting in persistent infection.	World J Gastroenterol.	20	3044-9	2014
Ikeda K, Izumi N, Tanaka E, <u>Yotsuyanagi H</u> , Takahashi Y, Fukushima J, Kondo F, Fukusato T, Koike K, Hayashi N, Tsubouchi H, Kumada H.	Discrimination of fibrotic staging of chronic hepatitis C using multiple fibrotic markers.	Hepatol Res.	44	1047-55	2014
Ito K, <u>Yotsuyanagi H</u> , Yatsuhashi H, Karino Y, Takikawa Y, Saito T, Arase Y, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, Mita E, Yamamoto K, Michitaka K, Ma	Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults.	Hepatology	59	89-97	2014

eshiro T, Tanuma J, Tanaka Y, Sugiyama M, Murata K, Masaki N, Mizokami M; Japanese AHB Study Group.					
Itakura J, <u>Kurosaki M</u> , Takada H, Nakakuki N, Matsuda S, Gondou K, Asano Y, Hattori N, Itakura Y, Tamaki N, Yasui Y, Suzuki S, Hosokawa T, Tsuchiya K, Nakanishi H, Takahashi Y, Maekawa S, Enomoto N & Izumi N.	Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to IL28B genotype and are sensitive to interferon-based therapy.	Hepatol Res		Epub ahead of print	2015
Tanaka T, Sugawara Y, Akamatsu N, Kaneko J, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, <u>Kurosaki M</u> , Izumi N, Kokudo N;	Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.	J Hepatobiliary Pancreat Sci.	22	144-150.	2015
Umemura T, Ota M, Katsuyama Y, Wada S, Mori H, Maruyama A, Shibata S, Nozawa Y, Kimura T, Morita S, Joshita S, Komatsu M, <u>Matsumoto A</u> , Kamijo A, Kobayashi M, Takamatsu M, Yoshizawa K, Kiyosawa K, Tanaka E.	KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.	Hum Immunol	75	822-826	2014
Kamijo N, <u>Matsumoto A</u> , Umemura T, Shibata S, Ichikawa Y, Kimura T, Komatsu M, Tanaka E.	Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion.	World J Gastroenterol.	21	541-548	2015
<u>Matsumoto A</u> , Yatsuhashi H, Nagaoka S, Suzuki Y, Hosaka T, Tsuge M, Chayama K, Kanda T, Yokosuka O, Nishiguchi S, Saito M, Miyase S, Kang JH, Shinkai N, Tanaka Y, Umemura T, Tanaka E.	Factors associated with the effect of interferon- α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B	Hepatol Res		Epub ahead of print	2015
<u>Suzuki F</u> , Toyota J, Ikeda K, Chayama K, Mochida S, Hayashi N, Ishikawa H, Miyagoshi H, Wenhua Hu, Fiona McPhee, Eric A Hughes, Kumada H	A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.	Antiviral Therapy	19	491-499	2014

<u>Suzuki F</u> , Hosaka T, Suzuki Y, Akuta N, Sezaki H, Hara T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H	Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine.J Gastroenterol.	J Gastroenterol	49	1094-1104	2014
Hara T, <u>Suzuki F</u> , Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Kumada H	Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naive chronic hepatitis B patients.	J Viral Hepat	21	802-808	2014
<u>Suzuki F</u> , Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Suzuki Y, Kumada H	Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.	Drug Des Devel	8	869-873	2014
Ikeda K, Kawamura Y, Kobayashi M, Fukushima T, Sezaki H, Hosaka T, Akuta N, Saitoh S, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H	Prevention of disease progression with anti-inflammatory therapy in patients with HCV-related cirrhosis: A Markov model.	Oncology	86	295-302	2014
Akuta N, <u>Suzuki F</u> , Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H	Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b.	J Med Virol	86	1314-1322	2014
Akuta N, <u>Suzuki F</u> , Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H	Utility of Detection of Telaprevir-Resistant Variants for Prediction of Efficacy of Treatment of Hepatitis C Virus Genotype 1 Infection.	JCM	52	193-200	2014
Akuta N, <u>Suzuki F</u> , Kobayashi M, Hara T, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H	Correlation Between Hepatitis B Virus Surface Antigen Level and Alpha-Fetoprotein in Patients Free of Hepatocellular Carcinoma or Severe Hepatitis.	J Med Virol	86	131-138	2014

Arase Y, Kobayashi M, Kawamura Y, <u>Suzuki F</u> , Suzuki Y, Akuta N, Kobayashi M, Sezaki H, Saitoh S, Hosaka T, Ikeda K, Kumada H, Kobayashi T	Impact of Virus Clearance for the Development of Hemorrhagic Stroke in Chronic Hepatitis C.	J Med Virol	86	169-175	2014
Tanaka M, <u>Suzuki F</u> , Seko Y, Hara T, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H	Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.	J Gastroenterol	49	470-480	2014
Kobayashi M, Hosaka T, <u>Suzuki F</u> , Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H	Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up.	J Gastroenterol	49	538-546	2014
Kawakami Y, <u>Suzuki F</u> , Karino Y, Toyota J, Kumada H, Chayama K	Telaprevir is effective given every 12 h at 750mg with pegylated interferon- α 2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.	Antiviral Therapy	19	277-285	2014
Hosaka T, <u>Suzuki F</u> , Kobayashi M, Fukushima T, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H	HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleoside analogue therapy.	Liver Int		Epub ahead of print	2014
Kawamura Y, Ikeda K, Fukushima T, Hara T, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, <u>Suzuki F</u> , Suzuki Y, Kumada H	Potential of a no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: An experimental animal study.	Hepatol Res		Epub ahead of print	2014
Sezaki H, <u>Suzuki F</u> , Hosaka T, Akuta N, Fukushima T, Hara T, Kawamura Y, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H	Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients.	Hepatol Res	44	163-171	2014

Kumada H, Sato K, Takehara T, Nakamura M, Ishigami M, Chayama K, Toyota J, <u>Suzuki F</u> , Nakayashu Y, Ochi M, Yamada I, Okanoue T	Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan.	Hpatol Res		Epub ahead of print.	2014
Tatsumi A, Maekawa S, Sato M, Komatsu N, Miura M, Amemiya F, Nakayama Y, Inoue T, <u>Sakamoto M</u> , Enomoto N.	Liver Stiffness Measurement for Risk Assessment of Hepatocellular Carcinoma.	Hepatol Res	Article first published online : 20 OCT 2014, DOI: 10.1111/hepr.12377	Epub ahead of print.	2015
Miura M, Maekawa S, Sato M, Komatsu N, Tatsumi A, Takano S, Amemiya F, Nakayama Y, Inoue T, <u>Sakamoto M</u> , Enomoto N.	Deep sequencing analysis of variants resistant to the NS5A inhibitor daclatasvir in patients with genotype 1n hepatitis C virus infection.	Hepatol Res	Article first published online : 10 APR 2014, DOI: 10.1111/hepr.12316	Epub ahead of print.	2015
Komatsu N, Motosugi U, Maekawa S, Shindo K, <u>Sakamoto M</u> , Sato M, Tatsumi A, Miura M, Amemiya F, Nakayama Y, Inoue T, Fukasawa M, Uetake T, Ohtaka M, Sato T, Asahina Y, Kurosaki M, Izumi N, Ichikawa T, ¥ Araki T, Enomoto N.	Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging.	Hepatol Res	44	1339-1346	2014
Nagaoki Y, Imamura M, <u>Kawakami Y</u> , Kan H, Fujino H, Fukuhara T, Kobayashi T, Ono A, Nakahara T, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawakami T, Tsuge M, Hiramatsu A, Aikata H, Takahashi S, Hayes CN, Ochi H, Chayama K; Hiroshima Liver Study Group.	Interferon lambda 4 polymorphism effects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C.	Hepatol Res.		Epub ahead of print.	2014
Fujino H, Imamura M, Nagaoki Y, <u>Kawakami Y</u> , Abe H, Hayes CN, Kan H, Fukuhara T, Kobayashi T, Masaki K, Ono A, Nakahara T, Honda Y, Naeshiro N, Urabe A, Yokoyama S, Miyak	Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.	J Gastroenterol.	49	1548-1556	2014

i D, Murakami E, Kawakami Y, Hiraga N, Tsuge M, Hiramatsu A, Hyogo H, Aikata H, Takahashi S, Miki D, Ochi H, Ohishi W, Chayama K; Hiroshima Liver Study Group.					
<u>Kawakami Y</u> , Suzuki F, Karino Y, Toyota J, Kumada H, Chayama K.	Telaprevir is effective given every 12 hours at 750 mg with peginterferon-alfa-2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.	Antivir Ther.	19	277-285	2014
Nakaoka K, Hashimoto S, Kawabe N, Nitta Y, Murao M, Nakano T, Shimazaki H, Kan T, Takagawa Y, Ohki M, Kurashita T, Takamura T, Nishikawa T, Ichino N, Osakabe K, <u>Yoshioka K</u> .	PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients.	SpringerPlus	4(1)	83	2015
<u>Yoshioka K</u> , Hashimoto S, Kawabe N	Measurement of liver stiffness as a non-invasive method for diagnosis of non-alcoholic fatty liver disease	Hepatology Res	45(2)	142-51	2015
Honda T, Ishigami M, Masuda H, Ishizu Y, Kuzuya T, Hayashi K, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, <u>Yoshioka K</u> , Toyoda H, Kumada T, Katano Y, Goto H	Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C	J Gastroenterol Hepatol	30(2)	321-8	2015
Hayashi K, Katano Y, Ishizu Y, Kuzuya T, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, <u>Yoshioka K</u> , Toyoda H, Kumada T, Goto H	Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C	J Gastroenterol Hepatol	30(1)	178-83	2015
Ichino N, Osakabe K, Sugimoto K, Suzuki K, Yamada H, Takai H, Sugiyama H, Yukitake J, Inoue T, Ohashi K, Hata H, Hamajima N, Nishikawa T, Hashimoto S, Kawabe N, <u>Yoshioka K</u>	The NAFLD Index: A Simple and Accurate	Rinsho Byori	63	32-43	2014
Nishikawa T, Hashimoto S, Kawabe N, Harata M, Nitta Y, Murao M, Nakano N, Mizuno Y, Shimazaki H, Kan T, Nakaoka K, Takagawa Y, Ohki M, Ichino N, Osakabe K, <u>Yoshioka K</u> .	Factors correlating with acoustic radiation force impulse elastography in chronic hepatitis C	World J Gastroenterol.	20(5)	1289-1297	2014

Shakado S, Sakisaka S, Okanou T, Chayama K, Izumi N, Toyoda J, Tanaka E, Ido A, Takehara T, <u>Yoshioka K</u> , Hiasa Y, Nomura H, Seike M, Ueno Y, Kumada H	Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan.	Hepatol Res	44(9)	983-992	2014
川部直人、橋本千樹、原田雅生、新田佳史、村尾道人、中野卓二、嶋崎宏明、水野裕子、菅敏樹、中岡和徳、大城昌史、高川友花、福井愛子、吉岡健太郎	C型肝炎治療困難例に対する瀉血療法、IFN-療法、脾摘/PSE後のPeg-IFN療法の検討	消化器内科	58(3)	405-412	2014
高川友花、川部直人、橋本千樹、原田雅生、村尾道人、新田佳史、中野卓二、嶋崎宏明、水野裕子、菅敏樹、中岡和徳、大城昌史、 <u>吉岡健太郎</u>	C型肝炎硬変に合併した多発肝MA LTリンパ腫の1例	肝臓	55(5)	274-283	2014
Kawaguchi T, Nagao Y, Abe K, Imazeki F, Honda K, Yamasaki K, Miyanishi K, Taniguchi E, Kakuma T, Kato J, <u>Seike M</u> , Yokosuka O, Ohira H, Sata M.	Effects of branched-chain amino acids and zinc-enriched nutrients on prognosticators in HCV-infected patients: a multicenter randomized controlled trial.	Mol Med Rep.	11(3)	2159-66.	2015
Kawaguchi T, Kohjima M, Ichikawa T, <u>Seike M</u> , Ide Y, Mizuta T, Honda K, Nakao K, Nakamuta M, Sata M.	The morbidity and associated risk factors of cancer in chronic liver disease patients with diabetes mellitus: a multicenter field survey.	J Gastroenterol.			2014
Shakado S, Sakisaka S, Okanou T, Chayama K, Izumi N, Toyoda J, Tanaka E, Ido A, Takehara T, Yoshioka K, Hiasa Y, Nomura H, <u>Seike M</u> , Ueno Y, Kumada H.	Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan.	Hepatol Res.	44	983-992	2014
Shakado S., Sakisaka S., Okanou T., Chayama K., Izumi N., Toyoda J., Tanaka E., Ido A., Takehara T., Yoshioka K.,	Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter	Hepatology Research	44(9)	983-92.	2014

Hiasa Y., Nomura H., Seike M., <u>Ueno Y.</u> , Kumada H.	retrospective study in Japan.				
Ninomiya M., <u>Ueno Y.</u> , Shimosegawa T.	Application of deep sequence technology in hepatology.	Hepatology Research	44(2):	141-8	2014
Omata M., Nishiguchi S., <u>Ueno Y.</u> , Mochizuki H., Izumi N., Ikeda F., Toyoda H., Yokosuka O., Nirei K., Genda T., Umemura T., Takehara T., Sakamoto N., Nishigaki Y., Nakane K., Toda N., Ide T., Yanase M., Hino K., Gao B., Garrison K. L., Dvory-Sobol H., Ishizaki A., Omote M., Brainard D., Knox S., Symonds W. T., McHutchison J. G., Yatsuhashi H., Mizokami M.	Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.	Journal of Viral Hepatitis	21(11)	762-8.	2014